Announced Wed, 19 Nov, 2025 · 11:18 IST
Granules India Q2 FY26: Revenue up 34% YoY, margins improve
Mgmt Guided Margin ImprovementOrder Pipeline DisclosedMgmt Evaded Key QuestionInvestor Communications View source PDFExplain this filing
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.1%1-day move
₹560.50
prior close
₹555.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.0+0.0+0.1-2.1-3.0-5.1-2.6-2.4-0.4-0.3+4.1+2.4+2.6
Up moveDown movePending
AI summary
Q2 FY26 revenue rose 34% YoY to Rs 12,970 crore, driven by formulations in North America and Europe. Gross margin expanded 368 bps to 65.7 percent, EBITDA margin up 42 bps YoY to 21.5 percent. Gagillapur FDA remediation on track with January 2026 meeting. Genome Valley facility received first FDA approval, adding 10 billion doses capacity. Ascelis Peptides targets profitability by Q4 FY26. Net debt rose to Rs 10,241 crore on higher CAPEX. ROCE at 16.2 percent.
Likely market impact
Strong execution with margin gains and regulatory progress supports growth recovery, but Ascelis losses and higher debt are near-term concerns.